In this debut episode of The UroOnc Minute, host Adam Weiner, MD, a urologic oncologist and surgeon-scientist at Cedars-Sinai Medical Center, introduces listeners to a new Urology Times podcast ...
The phase 3 PRESTO trial (NCT03009981) assessed combined androgen signaling blockade for a finite treatment period of 52 weeks in patients with high-risk biochemically relapsed prostate cancer. In ...
The key finding was that men who received rectal spacers had a 50% lower risk of biochemical failure. In this video, Sean P. Collins, MD, PhD, a radiation oncologist at Tampa General Hospital in Tampa ...
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025. Host Amy Pearlman, MD, discusses premature ejaculation with Brian L. Steixner, MD, a ...
Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...
The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 ...
The NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy in MIBC patients did not negatively impact HRQOL outcomes. Significant improvement in event-free survival was observed with ...
Apolo highlighted the positive topline results from the phase 3 EV-303 trial (NCT03924895) evaluating EV plus pembrolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer. In ...
Niraparib addition to abiraterone and prednisone improved rPFS in mCSPC patients with HRR gene alterations, especially those with BRCA mutations. The trial emphasized the importance of genomic testing ...
Casdatifan showed a 35% confirmed ORR in the 100 mg cohort, with median PFS not reached, indicating promising efficacy. The pooled analysis revealed a 31% ORR and a median PFS of 12.2 months, ...
EG110A targets type C sensory neurons to manage neurogenic detrusor overactivity-related incontinence, preserving other bladder controls. Fast track designation by the FDA allows EG110A to benefit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback